Abstract
The human ABO blood group system is of great importance in blood transfusion and organ transplantation. ABO transcription is known to be regulated by a constitutive promoter in a CpG island and regions for regulation of cell-specific expression such as the downstream + 22.6-kb site for epithelial cells and a site in intron 1 for erythroid cells. Here we investigated whether the + 22.6-kb site might play a role in transcriptional regulation of the gene encoding odorant binding protein 2B (OBP2B), which is located on the centromere side 43.4 kb from the + 22.6-kb site. In the gastric cancer cell line KATOIII, quantitative PCR analysis demonstrated significantly reduced amounts of OBP2B and ABO transcripts in mutant cells with biallelic deletions of the site created using the CRISPR/Cas9 system, relative to those in the wild-type cells, and Western blotting demonstrated a corresponding reduction of OBP2B protein in the mutant cells. Moreover, single-molecule fluorescence in situ hybridization assays indicated that the amounts of both transcripts were correlated in individual cells. These findings suggest that OBP2B could be co-regulated by the + 22.6-kb site of ABO.
Similar content being viewed by others
Introduction
The human ABO blood group system is of great importance in blood transfusion and organ transplantation. The carbohydrate structures of ABO blood group antigens are produced by the A- and B-transferases encoded by the A and B alleles, respectively1. The ABO genes are composed of seven exons which span approximately 20 kb of genomic DNA. The difference between the A and B alleles involves two critical single-base substitutions in exon 7, causing amino acid substitutions that are responsible for the difference in donor nucleotide sugar substrate specificity between the A- and B-transferases2. Most O alleles are associated with a single base deletion with a frame shift in exon 6, leading to abolition of A-transferase activity. ABO transcription is known to be regulated by a constitutive promoter in a CpG island and regions for regulation of cell-specific expression such as the downstream + 22.6-kb site for epithelial cells and the + 5.8-kb site in intron 1 for erythroid cells (Fig. 1)3,4,5,6,7. The + 22.6-kb site is located 22.6 kb downstream from the ABO transcription start site, and has also been shown to bind the epithelial cell-specific factor Elf56, while the + 5.8-kb site binds transcription factor RUNX1 and the erythroid cell-specific factors GATA-1 and -25,8,9. The functional significance of the promoter and the + 5.8-kb site has been verified by the presence of mutations found in some weak phenotypes such as A3, Am, B3, and Bm5,8,9,10,11,12,13,14. It has also been suggested that the transcriptional regulation of ABO is responsible for distribution of the A- and B-antigens in a cell-type-specific manner5,6, the change in ABO expression during cell differentiation15, and the decrease of A/B-antigen expression in cancer cells or on red blood cells of patients with leukemia16,17,18,19,20,21.
Individual chromosomes are segregated preferentially into separate territories during interphase22. Within these individual chromosome territories, the positioning of genomic regions is correlated with transcriptional activity. One compartment is termed component A (active), and the other is termed compartment B (inactive). These compartments were identified through Hi-C, which is a methodology for measuring the intensities of interaction between any pair of regions in the genome22. Another major type of chromatin organization is a self-interacting domain termed the topologically associating domain (TAD) or contact domain23,24,25. In mammalian cells, TAD boundaries are usually demarcated by the chromatin architectural protein CCCTC-binding factor (CTCF) and cohesin23,24,26,27,28. The TAD boundaries preferentially remain stable across cell types, while a small subset of boundaries show cell-type specificity23,29,30. In addition, the two interacting DNA sites bound by the CTCF protein and occupied by the cohesin complex form chromosome loop structures: some TADs involve a single loop, while others include multiple loops31. These loops frequently contain more than one gene, a feature which could facilitate the co-regulation and co-expression of genes located within the same loop32,33,34. Recently, Giammartino et al. reported that disruption of the KLF4 binding site within the Tbx3 enhancer weakened enhancer-promoter contacts and diminished the expression of Tbx3, Gm16063 and Aw549542 in pluripotent stem cells35.
In the present study using the gastric cancer cell line KATOIII, as the gene encoding odorant binding protein 2B (OBP2B) is located on the centromere side 43.4 kb from the + 22.6-kb site (Fig. 1), we demonstrated that the OBP2B transcripts were reduced in mutant cells with biallelic deletions of the + 22.6-kb site which were created by the CRISPR/Cas9 system, relative to the amounts of transcript in the wild-type cells. Moreover, single-molecule fluorescence in situ hybridization assays indicated that the amounts of both ABO and OBP2B transcripts were correlated in individual cells. These observations appear to provide new insight into the network of gene regulation between ABO and OBP2B in the neighbourhood of ABO.
Results
Involvement of the + 22.6-kb site of ABO in transcriptional regulation of OBP2B
Publicly available data for GeneHancer Regulatory Elements and Gene Interactions on the UCSC Genome Browser indicated that region GH09J133250 including the + 22.6-kb site interacted with transcription start sites of genes such as OBP2B, LCN1P1, SURF6, SURF1, and ADAMTS13 around ABO (Fig. 1, Table 1)36,37. In addition, publicly available data derived from chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) on the UCSC Genome Browser indicated that OBP2B, ABO, and the + 22.6-kb site were included within most CTCF-anchored loops formed around OBP2B or ABO in the breast cancer cell line MCF-7, which is representative of epithelial cells, whereas SURF6, SURF1, ADAMTS13, ABO, and the + 22.6-kb site were involved within a few CTCF-anchored loops (Fig. 1)38. This suggested that the + 22.6-kb site might preferentially regulate OBP2B rather than SURF6, SURF1, and ADAMTS13.
To examine whether the + 22.6-kb site was involved in transcriptional regulation of OBP2B, we performed RNA-seq and quantitative PCR using wild-type KATOIII cells and derived clones B3 and B4 harboring biallelic deletions of the + 22.6-kb site created using the CRISPR/Cas9 system6. RNA-seq indicated that the biallelic deletions resulted in loss of 94‒96% of the OBP2B transcript in B3 and B4 cells relative to the wild-type cells, and in loss of 72‒81% of the ABO transcript (Fig. 2). To verify the decrease in the OBP2B transcript, real-time PCR was performed, and this demonstrated that the deletions resulted in loss of 39‒41% of the OBP2B transcripts and 35‒45% of the ABO transcripts (Fig. 2). Droplet digital PCR (ddPCR), which is appropriate for precise determination of the ratio of transcripts between the wild-type cells and mutant cells, demonstrated 46‒68% reduction of the OBP2B transcripts and 38‒62% reduction of the ABO transcripts in the mutant cells (Fig. 2). Thus, it appeared that the biallelic deletion of the + 22.6-kb site reduced transcription from OBP2B and ABO in the epithelial cells.
Since the GH09J133250 region is also known to interact with the transcription start sites of genes including LCN1P1, SURF6, SURF1, and ADAMTS13 other than OBP2B and ABO (Table 1), quantitative analysis was performed using real-time PCR and ddPCR (Fig. 2). For SURF6, a significant decrease in the transcripts was demonstrable only in B3 cells by real-time PCR, whereas ddPCR demonstrated no significant reduction of the transcripts in either B3 or B4 cells. Regarding SURF1, a significant reduction of the transcripts was demonstrated by real-time PCR in both mutant cell lines, whereas ddPCR did not indicate a significant decrease in either B3 or B4 cells. Regarding ADAMTS13, real-time PCR demonstrated a significant decrease of the transcripts in both mutant cell lines, whereas ddPCR demonstrated a significant decrease in B4 cells but not in B3 cells. Because LCN1P1 is a pseudogene, quantitative analysis was not carried out. Thus, it was uncertain whether biallelic deletions of the site led to a decrease of SURF6, SURF1, and ADAMTS13 transcripts in epithelial cells. In comparison with ABO and OBP2B, ADAMTS13 had a lower copy number, while SURF1 and SURF6 had higher copy numbers in KATOIII cells (data not shown). Because the amounts of these transcripts were near the lower or upper limit of the quantification range of the corresponding real-time PCR, and ddPCR is an absolute quantification test, this might have contributed to the discrepancies in the results between real-time PCR and ddPCR.
Human OBP2B and OBP2A are 97.5% identical to each other39. To examine whether the qPCRs were specific to OBP2B, the real-time PCR products were cloned into a cloning vector, followed by sequencing. Nucleotide determination of 12 clones demonstrated that every PCR product was derived from OBP2B on the basis of nucleotide substitutions from c.331 to c.503 in OBP2B with a reference sequence of NM_014581.3 where 11 nucleotide substitutions were present between OBP2B and OBP2A. In addition, RT-PCR was carried out using primers complementary to the consensus sequences for OBP2B and OBP2A with cDNA prepared from KATOIII cells, followed by cloning and sequencing. Nucleotide determination of 20 clones demonstrated that all products were derived from OBP2B on the basis of the nucleotide sequences from c.269 to c.503 in OBP2B where 16 nucleotide substitutions were present between OBP2B and OBP2A. Direct sequencing of the RT-PCR products did not detect nucleotide variants specific to OBP2A (data not shown). These results indicated that OBP2A was scarcely expressed in KATOIII cells.
Decrease of OBP2B protein expression in both the cell lysate and supernatant of mutant cells lacking the epithelial cell-specific regulatory region of ABO
To verify that OBP2B protein expression was reduced in the mutant clones B3 and B4 relative to that in wild-type KATOIII cells, Western blotting was performed using the cell lysate and supernatant. This revealed a decrease of OBP2B protein in both the cell extract and supernatant of the mutant cells relative to the wild-type cells (Fig. 3). Therefore, it was likely that the + 22.6-kb site played an important role in transcriptional regulation of OBP2B expression in cells of epithelial lineage. However, biallelic deletion of the + 22.6-kb site did not achieve complete loss of the OBP2B expression, suggesting additional regulatory regions to be involved in regulation of the expression.
Examination of OBP2B transcriptional regulation
The transcription initiation site as reported on the UCSC Genome Browser was located 42 nucleotides upstream from the translation start site of OBP2B36. To identify the promoter region of OBP2B, 5′-RACE was performed using cDNA synthesized from RNA of KATOIII cells. Agarose gel electrophoresis of the 5′-RACE products demonstrated a major band, and the DNA fragments were purified and cloned into a sequencing vector. The DNA sequences for 9 transformant clones were determined. The 5′-ends of the 5′-RACE products were located from 134‒44 nucleotides upstream from the translation start site of OBP2B, although the site at position − 134 was used most frequently as the transcription start site (Fig. 4).
In order to examine the transcriptional activity of the 5′ upstream sequences of OBP2B, we employed reporter and transfection systems. We first obtained reporter plasmid OBP1.4 by introducing the 1.4-kb genomic fragment 5′-flanking the coding sequence of OBP2B into the promoterless pGL3-basic vector upstream from the luciferase coding sequence (Fig. 5A). This plasmid was transiently transfected into KATO III cells. The promoter activity of the OBP1.4 construct was at least 15-fold higher than that of the pGL3-basic vector, and twofold lower than that of the pGL3-promoter vector containing the SV40 promoter. Deletion of the OBP2B upstream region from position − 1421 to − 552 resulted in a large decrease of luciferase activity, demonstrating that the important sequences for OBP2B transcription were contained within the deleted region. Further deletion of the sequence from − 552 to − 343 resulted in an increase of luciferase activity, suggesting that negative element(s) for the OPBP2B transcription were present within this deleted region. Furthermore, deletion of the sequence from − 343 to either − 229 or − 137 resulted in a large decrease of luciferase activity, confirming the importance of promoter sequences immediately upstream of the transcription start site (cap site) for OBP2B expression. Thus it appeared that the region from − 343 to − 41 was required for the promoter activity of OBP2B. Further study will investigate the upstream regions in detail to elucidate the OBP2B regulation involving the + 22.6-kb site.
Furthermore, the OBP2B promoter was proved to be enhanced by the + 22.6-kb site in KATOIII cells; introduction of the + 22.6-kb site downstream from luciferase resulted in an approximately twofold increase of luciferase activity relative to OBP0.3 in KATOIII cells (OBP0.3/C, Fig. 5B). In terms of cell specificity, the promoter was not active in K562 cells. In OUMS-36T-1 cells, the promoter was active, although its activity was not enhanced by the + 22.6-kb site (OBP0.3/C, Fig. 5B). These findings indicated that the OBP2B promoter activity was enhanced by the + 22.6-kb site in an epithelial cell-specific manner.
Involvement of the + 22.6-kb site in co-expression of ABO and OBP2B
To examine whether the ABO transcripts were correlated with the OBP2B transcripts, we performed single-molecule fluorescence in situ hybridization assays visualizing both transcripts in individual wild-type KATOIII cells (Fig. 6A). Analysis of more than 500 nuclei of the wild-type cells revealed that the expression of ABO was correlated with that of OBP2B in single cells with a coefficient of determination (R2) of 0.812 (Fig. 6D). Subsequently, to examine whether the + 22.6-kb site might contribute to co-expression of those genes, the hybridization assays were carried out in individual cells of the mutant clones B3 and B4 (Fig. 6B,C). Similar co-expression of ABO and OBP2B was observed in the mutant cells. Because R2 of B3 or B4 was 0.802 or 0.666, respectively (Fig. 6E,F), either was not as high as that of the wild-type cells. However, it remains to be investigated whether biallelic deletion of the + 22.6-kb site would increase the cell-to-cell variation of co-expression.
Discussion
In the present study, we demonstrated that OBP2B expression was reduced in gastric cancer cells with biallelic deletion of the epithelial cell-specific positive regulatory element of ABO, or the + 22.6-kb site, and that the OBP2B promoter activity was enhanced by the + 22.6-kb site as revealed by transient transfection of luciferase reporter plasmids into the epithelial cells. Therefore, these observations suggested that transcription of OBP2B and ABO was dependent upon the + 22.6-kb site, which functioned in an epithelial cell-specific manner. Moreover, single-molecule fluorescence in situ hybridization assays indicated a tendency for the two gene-neighborhoods OBP2B and ABO to have consistent activities, suggesting that genes in these neighborhoods could be co-regulated by the + 22.6-kb site. Long-range chromatin loops that are mediated by CTCF can facilitate enhancer–promoter interactions31,40, and could facilitate the co-regulation and co-expression of gene pairs32,33,34. Therefore, it seemed plausible that OBP2B and ABO were co-regulated by the epithelial cell-specific regulatory region of ABO.
Human OBP2A and OBP2B have been identified on 9q3439. Although they are homologous, they are differentially expressed in secretory structures. OBP2A is strongly expressed in lachrymal glands, nasal structures, salivary and lung, whereas OBP2B is expressed more strongly in such organs as the mammary glands and prostate. They belong to the lipocalin (LCN) family39, which includes a diverse group of low-molecular-weight proteins (18‒40-kDa)41. The LCNs are conserved through evolution and share an eight-stranded antiparallel β-sheet structure forming a barrel, which is the internal ligand-binding site that interacts with and transports small hydrophobic molecules including odorants, retinoids, steroid hormones, and lipids. Therefore, LCNs play important roles in physiological processes by binding to and transporting these small hydrophobic molecules. Odorant-binding proteins are thought to be secreted, and act by transporting hydrophobic molecules within mucus. The solubilization of odorant is the first step in the process of olfaction in the hydrophilic nasal mucus, since olfaction involves the binding of small, hydrophobic, volatile molecules to receptors of the nasal neuroepithelia, generating a cascade of neurological events that transmit information to the olfactory bulbs projecting into the brain. It is expected that OBP2B would be involved in lactation, since it is produced in the tubulo-acinar secretory cells of the mammary glands where ABH antigens are synthesized39. Although the species of odorant or lipid that binds to human OBP2B has remained elusive, it has been shown that rat OBP2 binds some odorous compounds such as chromopore 1-anilinonaphthalene 8-sulfonic acid, lilial (p-tert-butyl-α-methyl dihydrocinnamic aldehyde), and citralva (3,7-dimethyl-2,6-octadienenitile), as well as fatty acids such as myristic acid, palmitic acid, and stearic acid42. It has also been suggested that OBP2 is localized in the extracellular space43, which would be consistent with the present data indicating that OBP2 was secreted into the supernatant of cultured cells. Further investigation may help to clarify the species of odorants or lipids that bind to human OBP2B and the physiological processes that depend of their transport.
The present findings suggest that ABO and OBP2B are co-regulated in an epithelial cell-specific manner. Because OBP2B seems to be involved in physiological processes such as lactation, the regulatory element of ABO might play a pivotal role in the preservation of life or species. However, the physiological significance of ABO blood groups has not been clarified. Therefore, the biological role of the neighborhood gene controlled by the regulatory element of ABO might help to explain why the ABO gene has not been removed from the human genome during evolution.
Methods
Cells
We cultured the human gastric cancer cell line KATOIII (JCRB0611) and its derived clones B3 and B4 as described previously6. The human erythroleukemia cell line K562 (JCRB0019) and the human embryo fibroblast cell line OUMS-36T-1 (JCRB1006.1) were cultured as described previously6.
RNA-seq
RNA-seq analyses were performed by DNA ChIP Research Inc as described previously6. The raw RNA-Seq data were deposited and released in GEO, with the GEO accession GSE169059.
Quantitative PCR (qPCR)
RNA was prepared from the wild-type KATOIII cells and its derived clones B3 and B4, followed by cDNA preparation as reported previously5,15. Using real-time PCR with StepOne and SYBR Select (Thermo Fisher Scientific, Waltham, MA), the ABO and β-actin transcripts were quantified with gene-specific primers in accordance with the methods reported previously21, and the OBP2B, SURF6, SURF1, and ADAMTS13 transcripts were quantified according to the manufacturer’s protocol for the RT2 qPCR Primer Assay (QIAGEN GmbH, Hilden, Germany). Quantification of those transcripts except for β-actin was also performed using QX200 Droplet Digital PCR (ddPCR, Bio-Rad Inc., Hercules, CA). The transcript of 18S rRNA was also quantified by ddPCR with gene-specific primers according to the method reported previously21. Each 20 µL ddPCR reaction volume containing 10 µL of 2 × ddPCR EvaGreen SuperMix (Bio-Rad), 1 µL of cDNA diluted at 1:50, and 0.1 μM each gene-specific primer was prepared in a semi-skirted 96-well plate (Eppendorf AG, Hamburg, Germany). Following droplet generation on a QX200 droplet generator, the plate was sealed with PCR Plate Heat Seal, foil, pierceable (Bio-Rad), and PCR was carried out on a T100 or C1000 Touch thermal cycler (Bio-Rad). After PCR amplification, the plate was read using a QX200 droplet reader (Bio-Rad). QuantaSoft Analysis Pro software was used to assign positive/negative droplets and convert counts to copies/well. DNA fragments obtained by real-time PCR for OBP2B were then cloned into the pUC118 vector using a Mighty Cloning Reagent Set (Blunt End) (TaKaRa, Shiga, Japan). The nucleotide sequences of the amplified fragments were determined with a BigDye Terminator v1.1 Cycle Sequencing Kit (Thermo Fisher Scientific) with both M13 forward and reverse primers, and specific primers for the target. The sequencing run was performed on a SeqStudio Genetic Analyzer (Thermo Fisher Scientific).
Reverse transcription (RT)-PCR
PCR amplification was carried out using primers OBP2B + 231 and OBP2B + 554 whose sequences were 5′-GAAAATCCTGATGCGGAAGA-3′ and 5′-GGTGGTAGGGTGGGCTCT-3′, respectively. The conditions for PCR were 94 °C for 3 min, 35 cycles of 98 °C for 10 s, 60 °C for 15 s, and 68 °C for 30 s, followed by incubation at 68 °C for 7 min. DNA fragments obtained from RT-PCR were then cloned into the cloning vector, followed by sequencing as described above.
Western blot analysis
Whole-cell lysates were prepared from the wild-type KATOIII strain and its derived clones B3 and B4 using a Total Protein Extraction Kit (TaKaRa). Supernatant was prepared after the cells had been inoculated at 7 × 105/ml into serum-free medium 72 h prior to harvesting, followed by concentration with Amicon® Ultra-10K (Merck Millipore, Burlington, MA). Western blotting was carried out with rabbit anti-OBP2B monoclonal antibody (MA5-30722; Thermo Fisher Scientific) or anti-β-actin monoclonal antibody (017-24551; Wako, Osaka, Japan), followed by treatment with Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare, MA) and densitometry measurements with a LAS-3000 and MultiGauge v3.0 (FujiFilm, Tokyo, Japan).
5′-RACE
5′-RACE was performed using the SMARTer RACE 5′/3′ Kit (TaKaRa) in accordance with the manufacturer’s instructions. First-strand cDNA synthesis was primed using a modified oligo (dT) primer. After SMARTScribe Reverse Transcriptase (RT) reached the end of the mRNA template, it added several non-templated residues. The SMARTerIIA Oligonucleotide annealed to the tail of the cDNA served as an extended template for SMARTScribe RT. 5′-cDNA fragments were PCR-amplified using universal primer short and a gene-specific primer OBP2B + 237 whose sequence was 5′-GATTACGCCAAGCTTTCTGTGTCTGGTGGT-3′. The conditions for 5′-RACE cDNA amplification were 94 °C for 3 min, 40 cycles of 94 °C for 30 s, 68 °C for 30 s, and 72 °C for 3 min, followed by incubation at 72 °C for 10 min. The PCR products were electrophoresed through a 2% agarose gel, and DNA fragments were extracted using the MinElute Gel Extraction Kit (QIAGEN). The DNA fragments were then cloned into the cloning vector, followed by sequencing as described above.
Plasmids
DNA fragments from − 1421 to − 41 or from − 552 to − 41 relative to the translation start site of OBP2B were obtained by PCR amplification using the genomic DNA prepared from KATOIII cells as a template, followed by subcloning at the KpnI and NheI sites upstream of luciferase in the same orientation as that of luciferase in the pGL3 basic vector (Promega, Madison, WI) sequence in reporter plasmids OBP1.4 and OBP0.5, respectively. Deletion of the 5′-end of the upstream region of OBP2B was carried out by restriction enzyme digestion with ApaI, MboII or NcoI, followed by ligation into reporters OBP0.3, OBP0.2 or OBP0.1, respectively. The + 22.6-kb site was inserted into the BamHI and SalI sites downstream of luciferase to generate construct OBP0.3/C. The sequences of the inserts for all of the constructs used in this study were verified by detailed restriction enzyme mapping and DNA sequence analysis as described above. Plasmid DNA was purified using a HiSpeed Plasmid Maxi Kit (QIAGEN).
Transfection and luciferase assay
Transient transfection of KATOIII cells was carried out using Lipofectamine LTX reagent (Thermo Fisher Scientific) with 1 μg of reporter plasmid and 0.001 μg of pRL-SV40 Renilla reporter in accordance with the manufacturer’s instructions. Transient transfection of K562 cells or OUMS-36T-1 cells was performed as reported previously6. After collecting the cells, cell lysis and luciferase assays were performed using the Dual Luciferase Reporter Assay System (Promega) to measure the activities of firefly and Renilla luciferases. Variations in transfection efficiency were normalized to the activities of Renilla luciferase expressed from the cotransfected pRL-SV40 Renilla luciferase reporter.
Statistical analyses
All data are expressed as mean values and error bars representing standard deviation from at least three independent experiments. Data analyses for the two groups were performed using Student’s t test (*p < 0.05; **p < 0.01).
Single-molecule fluorescence in situ hybridization
The wild-type KATOIII cells, and their derived mutant clones B3 and B4 were seeded on chamber slides at 50% confluency one day before the assay. RNA fluorescence in situ hybridization assays were performed with RNAscope technology utilizing the RNAscope Fluorescent Multiplex Kit V2 Kit (Cat # 323100, ACD, Hayward, CA, USA) in accordance with the manufacturer’s instructions. Briefly, the slides were rinsed once with phosphate-buffered saline (PBS), fixed with 10% neutral buffered formalin solution for 30 min at room temperature (RT), then dehydrated in an ethanol series and rehydrated in PBS. The slides were then treated with 15-fold diluted RNAscope protease III for 10 min at RT, followed by incubation with RNAscope probes for ABO and OBP2B (Cat #583991 and 584031-C2, respectively: ACD) for 2 h at 40 °C and stored overnight in 4 × SSC buffer. The probes were fluorescently labeled with Opal Dyes (Perkin Elmer, Waltham, MA; Opal570 diluted 1:500 and assigned to ABO; Opal520 diluted 1:500 and assigned to OBP2B) and stained with DAPI to label the nuclei.
Image acquisition and signal quantification
The fluorescent images were acquired in the Z-series using a Zeiss LSM880 confocal microscope equipped with 40 × objectives. For each subject, five regions were selected randomly. Following image acquisition, in each region, the Z-series were compressed into one image using the “maximum intensity projection” method in ZEN black software, and the signal intensity was automatically adjusted by the Min/Max option, creating relative intensity. The images were then transferred to Fiji software for semi-quantitative analysis. First, based on the DAPI signals, the nuclei and background signals were separated based on an automatically selected threshold using the “Otsu” method in Fiji (version 1.53c)44. The overlapping nuclei were split by the “Watershed” function and each separated nucleus was assigned as a ROI. Then, the signals of ABO (Opal570) or OBP2B (Opal520) in each ROI were analyzed using the “Analyze Particle” function. Finally, the mean relative intensity of ABO (Opal570) or OBP2B (Opal520) in each ROI was measured and plotted. The regression curve and coefficient of determination (R2) were calculated in Excel using “data analysis” add-in.
References
Daniels, G. Human Blood Groups (ed. Daniels, G.). 21–25 (Wiley-Blackwell, 2013).
Yamamoto, F. Molecular genetics of ABO. Vox Sang. 78, 91–103 (2000).
Kominato, Y. et al. Alternative promoter identified between a hypermethylated upstream region of repetitive elements and a CpG island in human ABO histo-blood group genes. J. Biol. Chem. 277, 37936–37948 (2002).
Hata, Y. et al. Characterization of the human ABO gene promoter in erythroid cell lineage. Vox Sang. 82, 39–46 (2002).
Sano, R. et al. Expression of ABO blood-group genes is dependent upon an erythroid cell-specific regulatory element that is deleted in persons with the Bm phenotype. Blood 119, 5301–5310 (2012).
Sano, R. et al. Epithelial expression of human ABO blood-group genes is dependent upon a downstream regulatory element functioning through an epithelial cell-specific transcription factor, Elf5. J. Biol. Chem. 291, 22594–22606 (2016).
Kominato, Y., Sano, R., Takahashi, Y., Hayakawa, A. & Ogasawara, K. Human ABO gene transcriptional regulation. Transfusion 60, 860–869 (2020).
Nakajima, T. et al. Mutation of the GATA site in the erythroid cell-specific regulatory element of the ABO gene in a Bm subgroup individual. Transfusion 53, 2917–2927 (2013).
Takahashi, Y. et al. Deletion of the RUNX1 binding site in the erythroid cell-specific regulatory element of the ABO gene in two individuals with the Am phenotype. Vox Sang. 106, 167–175 (2014).
Cai, X. et al. Molecular genetic analysis of ABO blood group variations reveals 29 novel ABO subgroup alleles. Transfusion 53, 2910–2916 (2013).
Takahashi, Y. et al. Presence of nucleotide substitutions in transcriptional regulatory elements such as the erythroid cell-specific enhancer-like element and the ABO promoter in individuals with phenotypes A3 and B3, respectively. Vox Sang. 107, 171–180 (2014).
Sano, R. et al. A 3.0-kb deletion including an erythroid cell-specific regulatory element in intron 1 of the ABO blood group gene in an individual with the Bm phenotype. Vox Sang. 108, 310–313 (2015).
Oda, A. et al. A novel mutation of the GATA site in the erythroid cell-specific regulatory element of the ABO gene in a blood donor with the AmB phenotype. Vox Sang. 108, 425–427 (2015).
Isa, K. et al. Presence of nucleotide substitutions in the ABO promoter in individuals with phenotypes A3 and B3. Vox Sang. 110, 285–287 (2016).
Sano, R. et al. Blood group B gene is barely expressed in in vitro erythroid culture of Bm-derived CD34+ cells without an erythroid cell-specific regulatory element. Vox Sang. 108(302–9), 15 (2015).
Orlow, I. et al. Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors. Int. J. Cancer. 75, 819–824 (1998).
Kominato, Y. et al. Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region. J. Biol. Chem. 274, 37240–37250 (1999).
Gao, S. et al. Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma. Int. J. Cancer. 109, 230–237 (2004).
Chihara, Y. et al. Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. Lab. Investig. 85, 895–907 (2005).
Bianco-Miotto, T. et al. DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLoS ONE 4, e4788 (2009).
Hayakawa, A. et al. RUNX1 mutation in a patient with myelodysplastic syndrome and decreased erythrocyte expression of blood group A antigen. Transfusion 60, 184–196 (2020).
Lieberman-Aiden, E. et al. Comprehensible mapping of long-range interactions reveals principles of the human genome. Science 326, 289–293 (2009).
Dixon, J. R. et al. Topological domains in mammalian genome identified by analysis of chromatin interactions. Nature 485, 376–380 (2012).
Nora, E. P. et al. Spatial partitioning of the regulatory landscape of the X-inactivation centre. Nature 485, 381–385 (2012).
Sexton, T. et al. Three-dimensional folding and functional organization principles of the Drosophila genome. Cell 148, 458–472 (2012).
Zui, J. et al. Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells. Proc. Natl. Acad. Sci. U. S. A. 111, 996–1001 (2014).
Rao, S. S. et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 159, 1665–1680 (2014).
Vietri, M. et al. Comparative Hi-C reveals that CTCF underlies evolution of chromosomal domain architecture. Cell Rep. 10, 1297–1309 (2015).
Dixon, J. R. et al. Chromatin architecture reorganization during stem cell differentiation. Nature 518, 331–336 (2015).
Grubert, F. et al. Landscape of cohesin-mediated chromatin loops in the human genome. Nature 583, 737–743 (2020).
Hnisz, D., Day, D. S. & Young, R. A. Insulated neighborhoods: Structural and functional units of mammalian gene control. Cell 167, 1188–1200 (2016).
Grubert, F. et al. Genetic control of chromatin states in humans involves local and distal chromosomal interactions. Cell 162, 1051–1065 (2015).
Waszak, S. M. et al. Population variation and genetic control of modular chromatin architecture in humans. Cell 161, 1039–1050 (2015).
Battle, A. et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Res. 24, 14–24 (2014).
Giammartino, et al. KLF4 is involved in the organization and regulation of pluripotency-associated three-dimensional enhancer networks. Nat. Cell Biol. 21, 1179–1190 (2019).
http://genome.ucsc.edu/cgi-bin/hgTrackUi?db=hg19&g=geneHancer. Accessed 19 Jan 2020.
Fishilevich, S. et al. GeneHancer: Genome-wide integration of enhancers and target genes in GeneCards. Database 2017, bax028 (2017).
https://www.genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=889924671_r2ZG3NhgXAaypcXd4NTsBjeyBWdY&c=chrX&g=wgEncodeGisChiaPet. Accessed 8 July 2020.
Lacazette, E., Gachon, A. M. & Pitiot, G. A novel human odorant-binding protein gene family resulting from genomic duplicons at 9q34: Differential expression in the oral and genital spheres. Hum. Mol. Genet. 9, 289–301 (2000).
Zheng, H. & Xie, W. The role of 3D genome organization in development and cell differentiation. Nat. Rev. Mol. Cell Biol. 20, 535–550 (2019).
Charkoftaki, G. et al. Update on the human and mouse lipocalin (LCN) gene family, including evidence the mouse Mup cluster is result of an “evolutionary bloom”. Hum. Genom. 13, 11 (2019).
Löbel, D., Marchese, S., Krieger, J., Pelosi, P. & Breer, H. Subtypes of odorant-binding proteins—heterologous expression and ligand binding. Eur. J. Biochem. 254, 318–324 (1998).
https://www.genecards.org/cgi-bin/carddisp.pl?gene=OBP2B&keywords=OBP2B. Accessed 8 July 2020.
Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
Acknowledgements
This work was supported in part by KAKENHI from the Japan Society for the Promotion of Science (20K10551 to R.S., 19H03916 to Y.K.). This work was the result of using research equipment shared in the MEXT Project for promoting public utilization of advanced research infrastructure (Program for supporting the introduction of the new sharing system) Grant Number JPMXS0420600120. We thank Tomoko Miwa for preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
R.S. conceived, designed, coordinated, performed research, analyzed data, and wrote the paper; H.F., M.H., A.H., T.O., and R.K. performed research; Y.T. performed research of single molecule fluorescence in situ hybridization; H.T., J.T., and Y.K. wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sano, R., Takahashi, Y., Fukuda, H. et al. A cell-specific regulatory region of the human ABO blood group gene regulates the neighborhood gene encoding odorant binding protein 2B. Sci Rep 11, 7325 (2021). https://doi.org/10.1038/s41598-021-86843-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-021-86843-6
- Springer Nature Limited
This article is cited by
-
Novel evidence that the ABO blood group shapes erythropoiesis and results in higher hematocrit for blood group B carriers
Leukemia (2023)
-
Emergence of an erythroid cell-specific regulatory region in ABO intron 1 attributable to A- or B-antigen expression on erythrocytes in Hominoidea
Scientific Reports (2023)